Literature DB >> 17124248

Adalimumab: a new modality for Behçet's disease?

J A M van Laar, T Missotten, P L A van Daele, A Jamnitski, G S Baarsma, P M van Hagen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17124248      PMCID： PMC1856047          DOI： 10.1136/ard.2006.064279

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 2.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

3.  [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].

Authors:  J A M van Laar; A Jamnitski; G S Baarsma; P L A van Daele; P M van Hagen
Journal:  Ned Tijdschr Geneeskd       Date:  2006-04-01

4.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 5.  Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Andrea Doria; Luca Iaccarino; Franco Capsoni
Journal:  Autoimmun Rev       Date:  2005-03       Impact factor: 9.754

6.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

Review 7.  The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Authors:  Marc C Hochberg; Mark G Lebwohl; Scott E Plevy; Kathryn F Hobbs; David E Yocum
Journal:  Semin Arthritis Rheum       Date:  2005-06       Impact factor: 5.532

8.  Vgamma9Vdelta2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens.

Authors:  Georges M G M Verjans; P Martin van Hagen; Alexander van der Kooi; Albert D M E Osterhaus; G Seerp Baarsma
Journal:  J Neuroimmunol       Date:  2002-09       Impact factor: 3.478

Review 9.  Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.

Authors:  David G Stokes; Joel M Kremer
Journal:  Semin Arthritis Rheum       Date:  2003-08       Impact factor: 5.532
  9 in total
  28 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 3.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 4.  Biologic agents in the management of inflammatory eye diseases.

Authors:  Kira Michalova; Lyndell Lim
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

5.  Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Authors:  Nádia Emi Aikawa; Carla Gonçalves; Clovis Artur Almeida Silva; Célio Gonçalves; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

Review 6.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

7.  Behçet's Uveitis.

Authors:  Ilknur Tugal-Tutkun
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

8.  Successful treatment with adalimumab in a patient with coexisting Behçet's disease and ankylosing spondylitis.

Authors:  Necmettin Yildiz; Hakan Alkan; Fusun Ardic; Oya Topuz
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

9.  Managing Behçet's disease: An update on current and emerging treatment options.

Authors:  P La van Daele; J H Kappen; P M van Hagen; J Am van Laar
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

10.  Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease?

Authors:  Jan A M van Laar; Jasper H Kappen; Paul L A van Daele; P Martin van Hagen
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.